Tests CM338 injection for immunoglobulin A nephropathy, a kidney disease
Tests CM338 injection in adults with IgA nephropathy, a kidney disease.
Plain-language title generated from the registry record
Registry title: Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05775042, who can take part
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Keymed Biosciences Co.Ltd
- Trial code
- NCT05775042
- Record updated
- 15 October 2024
- Original description
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.Read full original descriptionShow less
A Phase II Clinical Study Evaluating the Efficacy and Safety of CM338 Injection in Subjects With Immunoglobulin A Nephropathy
This study is a multicenter, randomized phase II clinical study to evaluate Efficacy and safety, while observing pharmacokinetic profiles, pharmacodynamic effects, and immunogenicity of CM338 in subjects with Immunoglobulin A(IgA) nephropathy.
Inclusion: Male or female aged 18-75; Understand the nature of the study and sign the Informed Consent Form voluntarily; Take effective contraception measures throughout the study period.
Exclusion: Used other investigational drugs within 30 days before the first study administration; With previous history of Human immunodeficiency virus(HIV) infection; Treponema pallidum antibody positive in screening period; Major surgery is planned during the study; May have active Mycobacterium tuberculosis infection; Other reasons the investigator believes that the subject is not suitable to participate in this study.